Last reviewed · How we verify
Bupivacaine 0.25-0.5%
Bupivacaine 0.25-0.5% is a Local anesthetic Small molecule drug developed by Rabin Medical Center. It is currently in Phase 2 development for Local anesthesia for surgical procedures, Pain management for chronic conditions.
Bupivacaine is a local anesthetic that blocks nerve impulses, preventing pain.
Bupivacaine is a local anesthetic that blocks nerve impulses, preventing pain. Used for Local anesthesia for surgical procedures, Pain management for chronic conditions.
At a glance
| Generic name | Bupivacaine 0.25-0.5% |
|---|---|
| Sponsor | Rabin Medical Center |
| Drug class | Local anesthetic |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Anesthesiology |
| Phase | Phase 2 |
Mechanism of action
It works by inhibiting the sodium channels in the nerve cell membrane, which prevents the initiation and transmission of nerve impulses. This results in a temporary loss of sensation in the affected area.
Approved indications
- Local anesthesia for surgical procedures
- Pain management for chronic conditions
Common side effects
- Numbness
- Dizziness
- Headache
- Nausea
- Tinnitus
- Seizure
Key clinical trials
- Erector Spinae Block Vs Ketamine-based Multimodal Analgesia Protocol in Lumber Decompressive Surgery (NA)
- Comparison of Erector Spinae Plane Block (ESPB) With the Combination of Superficial Parasternal Intercostal Plane Block (SPIPB) and Serratus Anterior Plane Block (SAPB) in the Management of Postoperative Sternotomy Pain in Patients Undergoing Cardiac Surgery Via Sternotomy (NA)
- Bupivacaine Alone vs Bupivacaine With Tramadol in Local Anesthesia Procedures (PHASE3)
- Comparison of the Efficacy of Combined Transversus Thoracic Plane Block and Serratus Anterior Plane Block Versus Erector Spinae Plane Block in the Management of Sternotomy Pain (NA)
- The Effect of Epidural Anesthesia on Optic Nerve Sheath Diameter Measurements in Total Knee Prosthesis Surgery (NA)
- Analgesic Efficacy of Adding Different Doses of Dexmedetomidine as Adjuvants With Bupivacaine vs.Bupivacaine Only in Ultrasound-guided Erector Spinae Plane Block in Morbidly Obese Patients Undergoing Laparoscopic Bariatric Surgery. A Randomized Controlled Double Blinded Study.
- Efficacy of Nerve Blocks for Episodic Migraine (PHASE2)
- Comparison of Posterior QLB and QIPB in Pediatric Undescended Testis Surgery. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bupivacaine 0.25-0.5% CI brief — competitive landscape report
- Bupivacaine 0.25-0.5% updates RSS · CI watch RSS
- Rabin Medical Center portfolio CI
Frequently asked questions about Bupivacaine 0.25-0.5%
What is Bupivacaine 0.25-0.5%?
How does Bupivacaine 0.25-0.5% work?
What is Bupivacaine 0.25-0.5% used for?
Who makes Bupivacaine 0.25-0.5%?
What drug class is Bupivacaine 0.25-0.5% in?
What development phase is Bupivacaine 0.25-0.5% in?
What are the side effects of Bupivacaine 0.25-0.5%?
What does Bupivacaine 0.25-0.5% target?
Related
- Drug class: All Local anesthetic drugs
- Target: All drugs targeting Voltage-gated sodium channels
- Manufacturer: Rabin Medical Center — full pipeline
- Therapeutic area: All drugs in Anesthesiology
- Indication: Drugs for Local anesthesia for surgical procedures
- Indication: Drugs for Pain management for chronic conditions